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Introduction
Antipsychotic drugs are the primary medications for the treat-
ment of schizophrenia and other neuropsychiatric disorders 
with a psychosis component (e.g. amphetamine psychosis, psy-
chosis in Alzheimer’s disease, psychosis in Parkinson’s disease, 
etc.). Since the introduction of chlorpromazine in psychiatry in 
1952, about 50 additional antipsychotic drugs have been devel-
oped for the treatment of schizophrenia. They are all signifi-
cantly more effective than placebo and are often classified into 
two groups, typical (or first generation) and atypical (or second 
generation), with atypical drugs offering a reduced risk of 
extrapyramidal motor syndromes (EPS) (Kapur and Remington, 
2001), although recent studies have questioned the validity of 
such a classification system (Leucht et al. 2013). The differ-
ences in efficacy among various commonly prescribed antipsy-
chotic drugs are small yet robust, with clozapine being more 
efficacious than all the other drugs (e.g. amisulpride, olanzap-
ine, risperidone, paliperidone, zotepine, haloperidol, quetia-
pine, aripiprazole, etc.).
Much research on antipsychotic drugs has four interconnected 
goals in mind. The first one is to understand the mechanisms of 
action of antipsychotic drugs at various levels (e.g. molecular, 
cellular, neural network, and behavioral) in an attempt to answer 
the basic question of how antipsychotic drugs work to achieve 
their therapeutic effects (Kapur, 2003, Kapur et al., 2005). There 
have been attempts to link actions of antipsychotic drugs at vari-
ous receptor sites, notably dopamine D2, serotonin (5-HT)2A, and 
5-HT1A receptors (Kapur et al., 2003; Meltzer et al., 1989; 
Richtand et al., 2007; Seeman, 2000) to their behavioral mecha-
nisms of actions (Li et al., 2007). The second goal is to enhance 
our understanding of etiology and psychopathological mecha-
nisms relevant for psychosis. The rationale is that dysfunction of 
the molecular targets of antipsychotic drugs such as D2 and 
5-HT2A can be a possible cause of psychotic symptoms (Seeman, 
2008). The third one is to provide better assays for new drug dis-
covery. With the increase of our understanding of etiology of psy-
chosis, molecular and behavioral mechanisms of antipsychotic 
action, behavioral and molecular assays with better predictive 
validity could be developed to identify new compounds useful 
for psychosis (Allen et al., 2011). The final one, which falls in the 
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domain of behavioral neuroscience, is to use antipsychotic drugs 
as pharmacological tools to probe the neurochemical basis of 
behavior, as typical antipsychotic drugs such as haloperidol are 
potent D2 receptor antagonists and atypical drugs possess dual 
actions against serotonin 5-HT2A and dopamine D2 receptors. 
Research discussed in this review has been largely aimed at the 
first goal.
One important feature associated with repeated or chronic 
antipsychotic treatment is the alterations of drug sensitivity, a 
phenomenon largely ignored in the field of behavioral pharma-
cology in recent decades. In comparison to extensive research on 
changes of drug sensitivity induced by psychotomimetic drugs 
(e.g. amphetamine, cocaine and PCP etc.) (Pierce and Kalivas, 
1997; Robinson and Becker, 1986), antipsychotic-induced altera-
tions are not as well understood. This situation is peculiar given 
the fact that antipsychotics, like drugs of abuse, are often taken 
repeatedly by people for a prolonged period of time, and increase 
in antipsychotic response is thought to be an important mecha-
nism supporting the maintenance of antipsychotic effect (Kapur 
et al., 2006). One of the major issues which may have contributed 
to this lack of attention is the difficulty in demonstrating its exist-
ence consistently. For example, in animal studies using the pre-
pulse inhibition paradigm, alterations in antipsychotic drug 
sensitivity have never been consistently established among dif-
ferent antipsychotics (Geyer et al., 2001; Li et al., 2011). On the 
other hand, clinical studies often focus on the efficacy, tolerabil-
ity, and side effect profiles of individual drugs, overlooking the 
temporal course of changes in drug sensitivity. Also, changes in 
antipsychotic efficacy in human studies typically do not become 
apparent within a limited trial period. It often requires years of 
medication in order to induce such a change (e.g. supersensitivity 
psychosis, tardive dyskinesia (TD)).
Several years ago, when we started looking into this issue, 
there were limited and scattered reports. There was also a lack of 
terminology used to describe drug-induced long-term changes in 
drug sensitivity and no standardized approach to study these 
changes. Current psychiatrists and psychopharmacologists do not 
talk about long-term antipsychotic effects in these terms, let alone 
discuss their clinical implications. We thus borrowed two terms 
from the literature of drugs of abuse and defined “antipsychotic 
sensitization” and “antipsychotic tolerance” as reflecting the 
increased and decreased drug effects due to past drug use, respec-
tively. Antipsychotic sensitization and tolerance reflect the long-
term consequences of chronic antipsychotic drug treatment on 
the brain and behavioral functions and are thought to be mediated 
by drug-induced changes in neuroplasticity and basic psycho-
logical processes. Therefore, understanding the behavioral char-
acteristics and neurobiological underpinnings of antipsychotic 
sensitization and tolerance should greatly enhance our under-
standing of mechanisms of antipsychotic action, and may help 
future drug discovery and improve clinical treatment of schizo-
phrenia. This understanding may also provide a different per-
spective of looking at some clinical effects. For example, 
antipsychotic sensitization and tolerance may explain why some 
recent clinical trials of promising novel therapeutics fail to dem-
onstrate efficacy (Gill et al., 2014). The testing of novel com-
pounds is often done in patients exposed to antipsychotic drugs 
(comparators) for years and briefly withdrawn. Due to the 
(cross)-tolerance effect, it is possible that prior antipsychotic 
exposure history and subsequent withdrawal affects the response 
of the brain to novel drugs to the extent that it effectively masks 
the true efficacy of novel compounds. On the other hand, as clini-
cal responses of patients on novel compounds are often compared 
to those on treatment-as-usual (TAU) after a brief washout 
period. Re-exposure to the same drug may potentiate the TAU 
group’s clinical responses to the comparator drug, masking the 
true efficacy of novel compounds from another perspective. In 
addition to these implications for antipsychotic drug research, 
because antipsychotic sensitization and tolerance share many 
similarities with behavioral sensitization and tolerance induced 
by other psychoactive drugs such as psychostimulants (e.g. 
amphetamine, methamphetamine, nicotine, etc.), opioids, and 
dissociative anesthetics (e.g. phencyclidine, ketamine, MK-801) 
(Poulos et al., 1981; Robinson and Becker, 1986), studies of 
antipsychotic sensitization and tolerance could expand our 
understanding of sensitization and tolerance phenomena in gen-
eral, and introduce new research ideas, tools, approaches, and 
knowledge.
This review will provide an overview of recent research in 
this area. We will focus on animal work that examines the behav-
ioral characteristics of antipsychotic sensitization and tolerance, 
the possible underlying neurobiological mechanisms, their devel-
opmental impacts and clinical implications. To show the clinical 
relevance of these phenomena, human studies on antipsychotic 
sensitization and tolerance will be briefly reviewed at the begin-
ning. It should be noted that sensitization and tolerance can 
develop in various domains involving different organ systems 
(e.g. cardiovascular, liver, blood, endocrine, brain, etc.) (Diamond 
and Borison, 1986; See and Kalivas, 1996). Because the behavior 
and associated brain functions are the focal targets of antipsy-
chotics, we will restrict our use of antipsychotic sensitization and 
tolerance in the behavioral domain. Thus, we define antipsy-
chotic sensitization as the consequence of repeated drug treat-
ment that leads to increased behavioral effects of a drug, while 
antipsychotic tolerance as the decreased behavioral effects.
General issues
It is worth mentioning three general principles at the outset. 
Readers who are familiar with behavioral sensitization and toler-
ance associated with drugs of abuse can easily recognize them. 
First, sensitization and tolerance develop to the specific effects of 
a drug, not to a drug itself. Like many psychoactive drugs, antip-
sychotic drugs typically have multiple behavioral and physiolog-
ical effects due to their complex pharmacodynamic receptor 
actions (Miyamoto et al., 2005). It is thus possible that antipsy-
chotic sensitization and tolerance may develop to one effect of a 
drug, but not to another (Sun et al., 2009). It is also possible that 
sensitization is seen in one effect while at the same time tolerance 
is seen in others. Furthermore, the same drug may induce sensiti-
zation to a drug effect under some circumstances (e.g. dosage 
level, dosing regimen, and duration) but may induce tolerance to 
the same effect under other conditions (Stewart and Badiani, 
1993). The second point is that multiple processes and mecha-
nisms are involved in the development of antipsychotic sensitiza-
tion and tolerance. At the behavioral level, antipsychotic 
sensitization and tolerance reflect a general nonassociative learn-
ing and memory process in which an organism modifies its 
responses to an exogenous stimulus (e.g. a drug) based on its past 
experience with this stimulus. The learning and memory pro-
cesses involved in antipsychotic sensitization and tolerance are 
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not dissimilar to those involved in the basic forms of habituation 
and sensitization. Because the induction and expression of both 
effects depend on the context in which drug treatment occurs and 
on the specific motoric response that the drug targets (Feng et al., 
2013; Poulos and Hinson, 1982; Sun et al., 2014; Zhang and Li, 
2012), other associative processes (e.g. conditioning, drug-set-
ting, behavioral response) may also play a role in the develop-
ment of antipsychotic sensitization and tolerance. At the brain 
level, drug-induced plastic changes on receptor density, intracel-
lular signaling, electrophysiological property of neurons, and 
neuroanatomic volume are examples of many processes 
that antipsychotic sensitization and tolerance exert on. Goudie 
(1993: 313) suggested that all these different processes and 
mechanisms associated with behavioral sensitization and toler-
ance can be classified into two general categories: “higher level 
mechanisms involving instrumental and classical conditioning 
processes, and more molecular mechanisms involving functional 
and dispositional adaptations.” He also pointed out that it would 
be easier to “derive general “laws” of sensitization and tolerance 
at the level of the first class rather than the second.” The third 
point is that many experimental and pharmacological factors 
influence the development of antipsychotic sensitization and tol-
erance. Notable factors include treatment schedule, drug dose, 
and behavioral testing conditions (Barnes et al., 1990; Remington 
and Kapur, 2010). Under some conditions, these factors could 
even determine whether a sensitization or tolerance will be devel-
oped (Klein and Schmidt, 2003; Poulos et al., 1981). With these 
points in mind, we will first review some human studies that 
examined antipsychotic sensitization and tolerance and their 
roles in explaining therapeutic and side effects of antipsychotic 
treatment.
Clinical phenomena associated with 
antipsychotic sensitization and 
tolerance
Like other psychoactive drugs, antipsychotic drugs are known to 
induce various clinically relevant sensitization and tolerance 
effects in many behavioral domains, including both therapeutic 
and side effects (Emmett-Oglesby and Goudie, 1989), resulting 
from the brain’s adaptive responses to the bombardment of long-
term antipsychotic drug treatment (Konradi and Heckers, 2001; 
Schmitt et al., 2004). The observations that psychotic symptoms 
improve over time and extrapyramidal side effects get worst after 
years of medication could be considered examples of antipsy-
chotic sensitization. On the other hand, chronic antipsychotic 
treatment can also induce tolerance in certain behavioral domains, 
as evidenced by the findings that in comparison to patients with 
chronic antipsychotic treatment, first-episode schizophrenia 
patients respond to lower doses of antipsychotics; are more sensi-
tive to side effects; and have comparatively higher response rates 
than chronic schizophrenia patients (Lieberman et al., 1993; 
Kapur et al., 2000). These differences between drug naïve (first-
episode) and drug experienced patients could be interpreted as a 
result of tolerance developed in the drug experienced group. The 
same drug treatment may induce sensitization in some patients, 
but tolerance in others (Sramek et al., 1990). Admittedly, the 
terms “antipsychotic sensitization” and “antipsychotic tolerance” 
have not been frequently used in describing many clinical phe-
nomena. The above mentioned clinical phenomena could also be 
subject to other interpretations. However, as will become appar-
ent, classifying antipsychotic phenomena in the framework of 
sensitization and tolerance would provide a unified theory (the 
brain’s adaptation responses to the bombardment of long-term 
antipsychotic drug treatment) to better understand their underly-
ing mechanisms. In this section, the four best known phenomena 
consistent with the conceptualization of antipsychotic sensitiza-
tion and tolerance will be selectively reviewed, including: expo-
nential time course of symptom improvement, time-dependent 
sensitization (TDS), supersensitivity psychosis, and TD (Agid 
et al., 2003; Fallon and Dursun, 2011; Kapur et al., 2006).
Exponential time course of symptom 
improvement
When acute psychotic patients are treated with antipsychotic 
drugs, their symptoms improve gradually over time if they 
respond well to the chosen antipsychotic drugs. After 2–3 weeks 
of continuous treatment, a clear improvement can be noticed and 
patients report that they are less bothered by psychotic thoughts 
and bizarre perceptions (Kapur et al., 2006). Dopamine D2 recep-
tor blockade is achieved within hours after drug administration 
(Nordstrom et al., 1992; Tauscher et al., 2002), however, it is not 
well understood and heatedly debated as to why it still takes 2–3 
weeks in order to see clear therapeutic benefits. Traditionally, it is 
thought that the onset of antipsychotic response is delayed for 2–3 
weeks, even though the receptor actions of antipsychotic drugs are 
well established within minutes (Gelder et al., 2000). However, 
recent re-examinations of the time course of antipsychotic effect 
cast doubt on this long-held idea of delayed onset (Agid et al., 
2003; Kapur et al., 2005; Leucht et al., 2005). Agid et al. (2003) 
examined 42 double-blind, comparator-controlled studies (>7000 
patients) using a meta-analysis technique, and found that psy-
chotic symptoms improved within the first week of treatment and 
showed a progressive improvement over subsequent weeks, with 
the overall pattern of improvement approximating an exponential 
curve. In addition, Kapur et al. (2005) tested the hypothesis that 
psychosis improves within the first 24 h of antipsychotic treat-
ment. They found that patients with schizophrenia receiving olan-
zapine (10 mg i.m.) or haloperidol (7.5 mg i.m.) treatment showed 
greater resolution of overall symptoms than those receiving pla-
cebo. An independent change in the psychotic symptoms, which 
included conceptual disorganization, hallucinatory behavior, or 
unusual thought content, was evident for both medications within 
the first 24 h of treatment. Leucht et al. (2005) analyzed a large 
homogeneous database of original patient data from seven rand-
omized, double-blind studies of the efficacy of amisulpride in 
patients with schizophrenia spectrum disorders and found the 
same results. Therefore, the time course of the antipsychotic 
action reveals a progressively enhanced response to antipsychotic 
drugs, a sensitization-like pattern. It can be conceptualized that 
the reason that psychotic symptoms improve over time and follow 
an exponential curve is because antipsychotic effect intensifies 
with repeated drug administration.
TDS
TDS is a controversial concept that is not well understood. It 
refers to the observation that a brief exposure to a psychothera-
peutic drug such as antipsychotic or antidepressant drugs induces 
a clinical effect that grows with the passage of time (Antelman 
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et al., 2000), an effect indicative of antipsychotic sensitization. 
Antelman et al. (2000) have argued that TDS is a useful principle 
for the explanation of clinical improvement which grows with 
the passage of time, and a certain percentage of symptom 
improvement observed in patients is likely due to TDS. One 
direct implication is that “instead of managing disorders such as 
depression by multiple daily drug treatments, it may be possible 
to accomplish the same ends by treating once every few weeks.” 
(p. 354). As discussed above, psychotic symptoms do improve 
exponentially with the passage of time and with the increase of 
treatment duration (Agid et al., 2006; Kapur et al., 2006), but the 
relative contributions from each factor (i.e. time vs treatment 
duration) on symptom improvement has not been investigated. 
Currently, the most common practice in the clinic is to treat 
schizophrenic patients with antipsychotic drugs daily to achieve 
approximately 60%–80% of dopamine D2 receptor occupancy 
(Kapur, 1998). If we do not need to maintain a daily treatment 
schedule, it would avoid many side effects, including EPS and 
excess weight gain. Recent studies showing that dosing every 
2–3 days is sufficient to maintain antipsychotic efficacy in schiz-
ophrenic patients is in support of this practice and the TDS prin-
ciple (Remington et al., 2005, 2011). This finding suggests that 
upon initial exposure, physiological events initiated by a drug 
enhance the antipsychotic’s effects beyond its presence at the 
receptor, thereby inducing efficacy without requiring constant 
receptor binding. This idea is also supported by our recent pre-
clinical findings that risperidone and asenapine sensitization per-
sist and even increase to some degree with the passage of time 
(Gao and Li, 2013). More clinical and preclinical work is needed 
to determine how pharmacological factors and characteristics of 
patients influence TDS and identify relevant neurobiological 
mechanisms.
Supersensitivity psychosis
Supersensitivity psychosis refers to a drug-induced psychotic 
relapse following chronic neuroleptic treatment (Chouinard and 
Jones, 1980; Kirkpatrick et al., 1992). It has been reported that in 
some patients with schizophrenia, their psychotic symptoms 
return following withdrawal or decrease of doses of antipsy-
chotic drugs. Some patients also report experiencing negative 
effects in the process of drug withdrawal, including difficulty 
falling or staying asleep, mood changes, increases in anxiety/agi-
tation, difficulty concentrating/completing tasks, headaches, 
memory loss, nightmares, nausea, and vomiting etc. (Salomon 
et al., 2014). The underlying mechanism is suggested to be the 
drug-induced increase in the mesolimbic dopamine postsynaptic 
D2 receptors. It is well known, especially in preclinical studies, 
that chronic use of antipsychotic drugs often elicits dopamine 
supersensitivity (up-regulation of D2High receptors) (Seeman, 
2011). The idea is that the cessation of chronic antipsychotic 
treatment induces a compensatory increase in the mesolimbic 
dopamine function, leading to psychotic relapse. Because super-
sensitivity psychosis is behaviorally (e.g. delusions, hallucina-
tions, suspiciousness) and neurobiologically (e.g. increase in the 
mesolimbic dopamine function) similar to endogenous psycho-
sis, reinstatement of antipsychotic treatment is efficacious to 
reduce this syndrome. In those patients, it is often observed that a 
gradual increase in the dosage is necessary to maintain a thera-
peutic effect, possibly due to the fact that antipsychotic treatment 
is needed to control both the endogenous psychosis and super-
sensitivity psychosis. This drug-induced increase in dosage 
increase indicates the development of tolerance to antipsychotic 
effect. In other words, the appearance of supersensitivity psycho-
sis reflects the fact that chronic use of antipsychotic drugs causes 
a tolerance effect.
TD
TD is a human choreic movement disorder associated with 
chronic exposure to antipsychotic drugs, especially to those with 
strong dopamine receptor blocking capacity (e.g. haloperidol, 
chlorpromazine). Clinically, TD includes a broad spectrum of 
symptoms that develop after chronic use of antipsychotic drugs, 
including involuntary movements of the tongue, jaw, trunk, or 
extremities. Abnormal movements could appear during treatment 
or withdrawal from the treatment, and typically persist for at least 
one month. The incidence of TD has not dramatically reduced 
with the widespread use of atypical antipsychotic drugs, suggest-
ing that the common D2 blocking action of all antipsychotics is 
likely the main cause (Aquino and Lang, 2014).
TD is thought to reflect an antipsychotic sensitization effect in 
the side effect domain, as the syndromes emerge and deteriorate 
over time (however, see (Poulos et al., 1981)). The traditional view 
of the neurobiological mechanism of TD emphasizes the role of 
drug-induced upregulation of D2 function (D2 hypersensitisation) 
(Turrone et al., 2003), the same mechanism thought to be responsi-
ble for supersensitivity psychosis, although manifested in the 
motor function domain, not in the emotion and cognition domains. 
This distinction between TD and supersensitivity psychosis may 
be due to regional differences in D2 upregulation, with TD strongly 
associated with changes in the dorsal striatum, while supersensitiv-
ity psychosis with changes in the ventral striatum (including the 
nucleus accumbens) (Chouinard and Jones, 1980). Recently, the 
emphasis is shifted to the drug-induced synaptic plasticity in cor-
tico-striatal transmission in the striatum. It is suggested that the 
synaptic plasticity is maladaptive, resulting in an imbalance 
between direct and indirect pathways in the striatum, and leads to 
perpetuating abnormal movements even after drug withdrawal 
(Loonen and Ivanova, 2013). Other ideas such as drug-induced 
disturbances of oxidative stress response systems and impacts on 
serotonin receptors and GABAergic medium spiny neurons have 
also been proposed (Aquino and Lang, 2014). Regardless of the 
precise mechanisms, TD is a cluster of persistent abnormal move-
ment syndromes associated with long-term treatment with antipsy-
chotic drugs. With its strong developmental feature, it likely 
reflects an increase of motor impairment effects of certain antipsy-
chotic drugs, a type of antipsychotic sensitization.
Other phenomena
Other forms of antipsychotic sensitization and tolerance have 
been reported. For example, Williams et al. (1996) studied the 
time-based sensitization of cognitive impairment with haloperi-
dol. They gave 24 healthy male subjects placebo on Day 1 and 
haloperidol (2 mg) on Days 2 and 25 and tested their cognitive 
function before dosing, and over a 24-hour period after dosing on 
Days 1, 2, and 25. They observed a clear impairment of cognitive 
function at 6–8 h after administration of haloperidol on Day 2. 
More importantly, when a single-dose of haloperidol was given 
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again 25 days later, a greater level of impairment with earlier 
onset was noted in several tests in both treatment groups, indicat-
ing an antipsychotic sensitization effect. On the other hand, clo-
zapine tolerance has been observed in some patients treated with 
clozapine. They show withdrawal symptoms (e.g. nausea, vomit-
ing, insomnia, diarrhea, agitation, aggression, headache, etc.) 
(Touyz et al., 1978) and relapse to psychosis (Seppala et al., 
2005), often seen with the discontinuation of clozapine use.
Overall, clinical studies have identified several clinical phe-
nomena indicative of antipsychotic sensitization (e.g. exponential 
time course of symptom improvement, TDS, and TD) and antipsy-
chotic tolerance (e.g. supersensitivity psychosis, clozapine with-
drawal symptoms). However, most of them are descriptive and not 
mechanistic-oriented. After reviewing some recent clinical studies 
on antipsychotic tolerance, Goudie and Cole (2008: 815) con-
cluded that “it seems highly likely that all antipsychotic treatments 
induce clinically important neuroadaptations during chronic drug 
administration, although the nature of such neuroadaptations 
remains unclear.” The possible distinctive neuroadaptations asso-
ciated with sensitization and tolerance effect have not been 
explored. Sramek et al. (1990) conducted a retrospective review of 
neuroleptic dosages over a five-year period in 19 chronic schizo-
phrenic patients. They found that some patients developed toler-
ance, while others developed sensitization, as indicated by their 
consistent yearly increases or decreases in dosage, suggesting that 
individual factors are also important in determining the direction 
of change in drug sensitivity. Unfortunately, it is not clear what 
the important pharmacological and dispositional factors are that 
influence these individual differences. Furthermore, the theoreti-
cal framework adequate to explain antipsychotic sensitization and 
tolerance is lacking. In the following, we will turn to preclinical 
animal work which in some way addressed these issues.
Preclinical evidence for antipsychotic-
induced behavioral sensitization and 
tolerance
Sensitization and tolerance induced by antipsychotic drugs have 
a long research history. The first report of antipsychotic tolerance 
in English that can be found on the PubMed database is a study 
by Boyd (1960) who reported that Wistar rats developed toler-
ance to the motor suppressant and lethal effects of chlorproma-
zine over a period of 40 weeks when they were injected with 
increasing daily doses of chlorpromazine. Stille et al. (1971) also 
reported that tolerance occurred to repeated dosing with clozap-
ine (2.5–20 mg/kg, p.o) and thioridazine (5–20 mg/kg, p.o), but 
not to haloperidol or perphenazine in locomotor activity in mice. 
At the end of the 19 days of drug administration, clozapine, and 
thioridazine even caused an increase in locomotor activity, a sign 
of behavioral supersensitivity (Seeman et al., 2005). On sensiti-
zation, Antelman et al. (1986: 58) reported that a single injection 
of low, clinically relevant doses of haloperidol and fluphenazine 
hydrochloride causes catalepsy in rats that grows over time “such 
that one re-exposure to the same compound up to 8 weeks later 
results in a marked enhancement (i.e. sensitization) of this 
response.”
Over the years, many preclinical studies provide strong sup-
port for chronic antipsychotic-induced sensitization and tolerance 
(Antelman et al., 1986). For example, intermittent haloperidol 
treatment via daily injection is shown to cause a progressively 
potentiated catalepsy (Amtage and Schmidt, 2003), enhanced 
vacuous chewing movements (VCMs, a proxy for tardive dyski-
nesia in humans) over time (Turrone et al., 2003), enhanced sup-
pression of milk intake (Wolgin and Moore, 1992), enhanced 
disruption of conditioned avoidance responding (CAR) (Li et al., 
2007), enhanced impairment of reward-based lever pressing rates 
(Trevitt et al., 1998; Varvel et al., 2002), enhanced disruption of 
maternal behavior (Zhao and Li, 2009b), and enhanced inhibition 
of phencyclidine (PCP)-induced hyperlocomotion (Sun et al., 
2009).  A similar effect on the PCP-induced hyperlocomotion has 
also been found with repeated clozapine and olanzapine treat-
ment (Sun et al., 2009). In addition, repeated clozapine treatment 
is also shown to induce increasing numbers of myoclonic seizure-
like jerks in rats (Stevens et al., 1997). Finally, Kaempf and Porter 
(1987) demonstrated sensitization for the rate-suppressing effects 
of the typical antipsychotic pimozide.
With regards to the antipsychotic-induced tolerance, continu-
ous haloperidol treatment via osmotic mini-pump has been shown 
to cause a progressively decreased inhibition of spontaneous 
motor activity in rats (Carey and Deveaugh-Geiss, 1984), 
increased behavioral supersensitivity, as measured by increased 
amphetamine-induced locomotor activity following antipsychotic 
discontinuation (Samaha et al., 2007), and a progressively 
decreased disruption of avoidance responding over time (Samaha 
et al., 2008). Stanford and Fowler (1997) reported that clozapine-
treated rats exhibited tolerance to the drug’s suppressive effect on 
the amount of time that rats were in contact with a force-sensing 
target disk. Trevitt et al. (1998) found that repeated injections of 
clozapine, but not haloperidol enhanced its suppression of lever 
pressing in a fixed ratio 5 (FR-5, 5 presses result in one reward). 
Porter and colleagues have conducted a series of experiments to 
identify differences between the acute and subchronic effects of 
antipsychotic drugs on operant responding in rats. In one earlier 
study, they demonstrated that acute treatment with clozapine sig-
nificantly suppressed operant response rates on fixed-interval 
60-second responding. With repeated drug administration and 
testing, the clozapine-treated rats gradually developed tolerance 
to the drug effects and recovered back to the vehicle control levels 
after seven days of drug treatment (Kaempf and Porter, 1987). 
Later, their group reported that although acute clozapine (10 mg/
kg) significantly disrupted response rates and reinforcement rates 
and significantly increased response duration on a schedule of 
multiple random interval responding for food reinforcement, 
chronic administration of clozapine resulted in a development of 
tolerance (Villanueva and Porter, 1993). Varvel et al. (2002) also 
found that repeated clozapine produced a decrease in the rate of 
responding for food reward under a multiple FR 30/ fixed-interval 
(FI) 60-second schedule. More importantly, the degree to which 
clozapine tolerance develops appears to depend in part on the 
schedule of reinforcement, with more complete tolerance observed 
under a FI 60-second schedule (Kaempf et al., 1987), and only 
partial tolerance (approximately 50–75%) under a FR 30 schedule 
(Varvel et al., 2002; Villanueva et al., 1993). This differential toler-
ance was attributed to the different baseline levels of responding 
generated by these reinforcement schedules (Varvel et al., 2002). 
Clozapine-induced tolerance has also been observed in a drug dis-
crimination task (Goudie et al., 2007) and rat maternal behavior 
(Zhao and Li, 2009b). Taken together, antipsychotic sensitization 
and tolerance appear to be inevitable features associated with 
repeated drug treatment. Therefore, understanding the neurobio-
logical and behavioral factors that modulate the induction and 
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expression of sensitization/tolerance is expected to greatly 
enhance our understanding of the effects of clinical treatment.
As mentioned above, antipsychotic sensitization refers to the 
increased behavioral responsiveness to an antipsychotic drug due 
to past drug treatment history, while tolerance refers to the oppo-
site behavioral pattern (i.e. decreased responsiveness). In recent 
years, we developed a two-phase paradigm to study antipsychotic 
sensitization and tolerance. In the induction phase, different 
groups of animals are being repeatedly treated with various doses 
of an antipsychotic drug or vehicle for 3–7 days and tested in a 
behavioral model of antipsychotic activity (e.g. the conditioned 
avoidance response model) daily. In the expression phase, all ani-
mals are being challenged with a single dose of the drug and their 
performance in the test is compared. The magnitude of antipsy-
chotic sensitization and tolerance can be measured in two ways in 
both phases (Qin et al., 2013; Swalve and Li, 2012), similar to the 
ones used in the behavioral sensitization induced by psychostim-
ulants (Browman et al., 1998). The first index of antipsychotic 
sensitization or tolerance is revealed through a within-subjects 
comparison in the induction phase during which the behavioral 
effect of the drug is either stronger or weaker on the last day of 
drug treatment than that on the first day (e.g. a comparison 
between days 1 vs 5) (Zhang and Li, 2012). A second index is 
derived from a between-subjects comparison in the expression 
phase during which the behavioral responses of drug-pretreated 
and vehicle-pretreated animals are compared. With a between-
groups analysis, antipsychotic sensitization or tolerance is indi-
cated if drug-pretreated animals show a significantly greater or 
lower sensitivity to the drug challenge than vehicle-pretreated 
animals. Overall, it is believed that a between-subjects analysis 
provides a more “conservative” index of sensitization or toler-
ance (Browman et al., 1998), as this approach ensures that vari-
ables that could contribute to potential changes in behavior are 
present in both the drug and vehicle control groups. In some 
cases, the behavior affected by an antipsychotic drug (as an index 
of antipsychotic effect) is allowed to recover under the drug-free 
condition to the pre-drug and vehicle control level before the 
drug challenge, thus, any group difference found on the challenge 
test could only be attributed to past drug treatment history. This 
approach provides the strongest demonstration of antipsychotic 
sensitization and tolerance. Figure 1 illustrates such an approach 
in the conditioned avoidance response test of antipsychotic drugs.
It is well established that at clinically relevant doses, all clini-
cally approved antipsychotic drugs acutely suppress avoidance 
responding without altering unconditioned escape response in 
rats (Arnt, 1982; Wadenberg et al., 2001). Thus, the magnitude of 
avoidance suppression is frequently used as a validated behavio-
ral index of antipsychotic activity (Arnt, 1982; Bignami, 1978; 
Shannon et al., 1999; Van Der Heyden and Bradford, 1988; 
Wadenberg and Hicks, 1999). As Figure 1 shows, in the induction 
phase, antipsychotic sensitization or tolerance in this test is 
observed when the avoidance-disruptive effect of the drug 
increases or decreases in magnitude throughout the treatment 
period. In the expression phase, sensitization or tolerance is 
shown when the drug-treated animals exhibit a lower or higher 
avoidance response than those treated with vehicle (Li et al., 
2010). Several early studies have demonstrated both effects in 
the conditioned avoidance response test. For example, Fregnan 
Figure 1. A schematic depiction of the two-phase paradigm used to study antipsychotic sensitization and tolerance. In the induction phase, different 
groups of animals are being repeatedly treated with various doses of an antipsychotic drug or vehicle for 3–7 days and tested in a behavioral model 
of antipsychotic activity daily. Antipsychotic sensitization or tolerance is revealed through a within-subjects comparison in this phase during which 
the behavioral effect of the drug is either stronger or weaker on the last day of drug treatment than that on the first day. In the expression phase, all 
animals are being challenged with a single dose of the drug and their performance in the test is compared. Antipsychotic sensitization or tolerance is 
indicated if drug-pretreated animals show a significantly greater or lower sensitivity to the drug challenge than vehicle-pretreated animals.
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and Chieli (1980) found that the anti-avoidance effect of halop-
eridol started on the first testing day and was progressively 
enhanced with each subsequent drug administration (across-ses-
sion decline in avoidance responding). It reached a maximum 
level within 5–8 days. Kuribara and Tadokoro (1981) and 
Beninger et al. (1983) confirmed this finding and extended it to 
two other classes of antipsychotics, YM-08050, YM-08051 and 
pimizode respectively. Using a home-cage control group injected 
with drugs but not tested repeatedly for avoidance responding, 
they also showed that the across-session decline in avoidance 
responding was not due to the accumulation of the drugs with 
repeated dosing. Sanger (1985) showed that repeated administra-
tion of clozapine over four days induces a strong tolerance to the 
avoidance-disruptive effect of clozapine. It should be noted that 
many previous studies on antipsychotic sensitization and toler-
ance have not paid enough attention to the distinct processes of 
the induction and expression. Most of them only focused on the 
induction process. Figure 2 shows the results of haloperidol sen-
sitization in the conditioned avoidance response model in adult 
rats (Swalve and Li, 2012). The sensitization pattern is clearly 
demonstrated in both phases.
Similarly, it is possible to apply this basic paradigm to other 
behavioral tests of antipsychotic drugs. For example, the same 
paradigm has been used to demonstrate that repeated administra-
tion of olanzapine (also, risperidone, asenapine) or clozapine 
induces a potentiated (sensitization) or a decreased (tolerance) 
inhibition of the PCP-induced hyperlocomotion, respectively 
(Feng et al., 2013; Qin et al., 2013; Sun et al., 2009; Zhang and 
Li, 2012; Zhao et al., 2012), another preclinical test for antipsy-
chotic activity (Gleason and Shannon, 1997) (see Figure 4(a)). 
Furthermore, this paradigm could also be used to conduct cross-
sensitization or cross-tolerance studies by challenging animals 
with a different antipsychotic drug during the expression phase. 
As an example, Zhang et al. (2011) shows that rats previously 
treated with risperidone in the induction phase showed stronger 
reactivity to the avoidance-disruptive effect of olanzapine admin-
istered in the expression phase. Recently, a cross-sensitization 
from asenapine to olanzapine in both the conditioned avoidance 
response model (Figure 3) and the PCP-induced hyperlocomo-
tion model (Figure 4) has also been observed (Qin et al., 2013).
Factors that influence antipsychotic 
sensitization and tolerance
It is common knowledge that both pharmacological factors (e.g. 
dose, schedule, and route of drug administration, presence of 
other drugs, etc.) and nonpharmacological factors (e.g. environ-
mental stimuli, selected behavioral responses, passage of time, 
etc.) affect the development of behavioral sensitization and toler-
ance induced by psychoactive drugs (Emmett-Oglesby and 
Goudi, 1989). Behavioral sensitization and tolerance induced by 
antipsychotic drugs are no exceptions. This section selectively 
reviews relevant reports, illustrating the principles of how these 
two classes of factors exert their impacts on the induction and 
expression of antipsychotic sensitization and tolerance.
Pharmacological factors
Drug dose. Antipsychotic sensitization and tolerance are depen-
dent upon a number of factors including dose and number of 
exposures. In fact, it is well known that drug doses can even 
determine whether a sensitization effect or tolerance effect will 
be observed. The general observation is that a sensitization is 
Figure 2. (a) Effect of repeated haloperidol (HAL) treatment (0.025 mg/kg, sc, -60 min) on conditioned avoidance responding across sessions. 
Number of avoidance responses made by the rats on the final training day (drug-free), five days of drug exposure and two drug-free retesting 
sessions are expressed as mean+standard error of the mean (SEM). Rats received either 0, 1, 2, 3, 4, or 5 days of HAL according to their group, 
*p<0.05. (b) Effect of number of drug exposure days on final challenge day. All groups were injected with HAL (0.025 mg/kg) and avoidance 
responses were measured, *p<0.05. Adapted from Swalve N and Li M (2012) Parametric studies of antipsychotic-induced sensitization in the 
conditioned avoidance response model: Roles of number of drug exposure, drug dose, and test-retest interval. Behav Pharmacol 23: 380–391 with 
permission from Wolters Kluwer Health, Inc. 
VEH: vehicle; SC: subcutaneously; -60 min: 60 min before test.
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likely to occur if a low dose is being used, whereas a tolerance 
often results from a treatment with a higher dose. For instance, 
haloperidol at low and medium doses in rats (e.g. 0.25 mg/kg) 
cause a sensitization in a catalepsy test (Klein and Schmidt, 
2003), at high doses (e.g. 1.0 mg/kg) it tends to cause a tolerance 
(Ezrin-Waters and Seeman, 1977; Poulos and Hinson, 1982). 
Similarly, clozapine at the high and medium doses (e.g. 5.0 to 
10.0 mg/kg) causes a tolerance but at low doses (e.g. 1.0 mg/kg) 
cause a sensitization (Stevens et al., 1997). Thus, sensitization or 
tolerance may not be an intrinsic feature of any particular drug or 
its particular behavioral effect, but is modulated by drug dose.
Within a dose range that typically induces either a sensiti-
zation or tolerance, the higher the dose, the stronger the sen-
sitization or tolerance effect. This conclusion was recently 
demonstrated in the conditioned avoidance response test. Swalve 
and Li (2012) tested three doses of haloperidol (0.025, 0.05 and 
0.10 mg/kg) and three doses of olanzapine (0.5, 1.0 and 2.0 mg/
kg) using the two-phase paradigm. Rats were first repeatedly 
treated with haloperidol or olanzapine for three consecutive days 
and tested for avoidance response. Three days later, all of them 
were challenged with haloperidol or olanzapine. Haloperidol or 
olanzapine at the low dose was unable to induce a long-term sen-
sitization as assessed in the expression phase. In contrast, the 
medium or high doses induced robust sensitization with just three 
days of drug treatment. Similarly, Feng et al. (2013) showed that 
clozapine tolerance is dose-dependent, as a higher dose (e.g. 10 
mg/kg) induces a stronger tolerance than that induced by a lower 
one (2.5 or 5.0 mg/kg).
Number of drug administrations. Antipsychotic-induced 
sensitization and tolerance have drug memory-like property. 
From the learning and memory perspective, the induction and 
expression phases can be characterized as the training (i.e. 
acquisition) and memory testing phases. The number of drug 
injections can thus be conceptualized as the number of learning 
trials (sessions). Therefore, it is expected that the strength of anti-
psychotic sensitization and tolerance will be more prominent fol-
lowing a greater number of drug injections. In one study (Li 
et al., 2010), rats that were treated with olanzapine (1.0 mg/kg) 
for 3 days displayed a relatively less robust sensitization effect 
than those who were treated with the drug for 5-7 days in other 
studies (Li et al., 2007; Li et al., 2009a; Mead and Li, 2010). 
Swalve and Li (2012) compared 5 groups of rats that received 1 
to 5 days of drug administration and found that sensitization 
induced by haloperidol (0.025 mg/kg) or olanzapine (0.5 mg/kg) 
was only apparent in rats that received injections for 5 days. The 
groups that had 1 to 4 days of injections did not even have slightly 
lower avoidance levels on the challenge day; instead, their levels 
were no different from that of the vehicle control group. These 
results suggest that antipsychotic sensitization is dependent on 
the number of drug exposures, with more exposures leading to a 
stronger sensitization effect.
Figure 3. Prior asenapine (ASE) treatment increased sensitivity to ASE re-exposure and olanzapine (OLZ) exposure in the avoidance response. (as) 
Number of avoidance responses in the ASE (0.10 mg/kg) challenge test; (b) OLZ (0.50 mg/kg) challenge test and (c) clozapine (CLZ, 2.50 mg/kg) 
challenge test is expressed as mean+standard error of the mean (SEM), *p<0.05, **p<0.01 relative to the vehicle (VEH) group; #p<0.05 relative to 
the ASE 0.05 group. Adapted from Qin R, Chen Y and Li M (2013) Repeated asenapine treatment produces a sensitization effect in two preclinical 
tests of antipsychotic activity. Neuropharmacology 75C: 356–364 with permission from Elsevier.
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Drug dosing regimen. Previous work suggests that drug dosing 
regimens determine many features of long-term treatment out-
comes, with an intermittent and transient treatment (e.g. daily 
injection) tending to cause a sensitization effect while a continu-
ous treatment (e.g. osmotic minipump) causes a tolerance (Rem-
ington and Kapur, 2010). Indeed, it has been shown that continuous 
haloperidol or olanzapine exposure to rats via osmotic minipump 
caused a greater increase in VCMs (a proxy for tardive dyskinesia 
in humans) than transient subcutaneous injections (Turrone et al., 
2005). Similarly, continuous haloperidol treatment caused an 
attenuated disruption (tolerance) of avoidance responding (a mea-
sure of antipsychotic activity), while intermittent haloperidol treat-
ment potentiated avoidance disruption (sensitization) (Samaha 
et al., 2007, 2008). Recently, we also demonstrated that haloperi-
dol sensitization induced throughout adolescence in the condi-
tioned avoidance response test persisted into adulthood only when 
haloperidol was administered via daily injection. If haloperidol 
was administered via osmotic minipump, the sensitization effect 
was not apparent (Gao and Li, 2013). This differential response to 
intermittent versus continuous treatment probably reflects differ-
ential effects of antipsychotic drugs on dopamine systems, espe-
cially on postsynaptic D2 receptors (Samaha et al., 2007).
Drug-drug interactions. Most patients with schizophrenia are 
being treated with multiple psychotherapeutic drugs, such as anti-
psychotics, SSRIs and benzodiazepines in order to control their 
Figure 4. Prior asenapine (ASE) treatment increased the inhibition of PCP-induced hyperlocomotion upon asenapine re-exposure and on olanzapine 
(OLZ) and clozapine (CLZ) treatment in adult rats. (a) Locomotor activity was measured for 60 min after vehicle (for the vehicle (VEH)+VEH-1 group) 
or PCP (3.20 mg/kg, sc, for the other five groups) injection and expressed as mean+standard error of the mean (SEM) for each group. ASE  
(0.10 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (b) Locomotor activity was measured for 60 min after vehicle or PCP 
injection and expressed as mean+SEM for each group. OLZ (0.50 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (c) Locomotor 
activity was measured for 60 min after vehicle or PCP injection and expressed as mean+SEM for each group. CLZ (2.50 mg/kg, sc) was injected 30 
min before the vehicle or PCP injection. (n=8/group). Both the VEH+VEH-1 and VEH+VEH-2 groups were repeatedly injected with 0.9% saline for  
five consecutive days in the induction phase. The only difference was that on the challenge test days, the VEH+VEH-1 group was injected with  
ASE/OLZ/CLZ followed by another saline injection, whereas the VEH+VEH-2 group was injected with ASE/OLZ/CLZ followed by a PCP injection. 
**p⩽0.001 relative to VEH+VEH-1 group; #p<0.05, ##p≤0.001 relative to VEH+VEH-2; &p<0.05, &&p⩽0.004 relative to VEH+PCP; $p<0.05, 
$$p⩽0.009 relative to ASE 0.20+PCP group. Adapted from Qin R, Chen Y and Li M (2013) Repeated asenapine treatment produces a sensitization 
effect in two preclinical tests of antipsychotic activity. Neuropharmacology 75C: 356–364 with permission from Elsevier. 
PCP: phencyclidine.
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diverse symptoms and co-morbid anxiety and depression (Zumb-
runnen and Jann, 1998). This practice of psychotropic polyphar-
macy has raised some concerns regarding the efficacy, costs and 
possible adverse effects of drug-drug interactions (DDIs) (Alfaro, 
2001; Rupnow et al., 2007; Sandson et al., 2005). However, because 
current clinical data come mostly from case reports and limited 
uncontrolled studies, it is difficult to assess the extent and nature of 
DDIs and determine how antipsychotic sensitization or tolerance 
might be altered by DDIs. A few years ago, a drug-drug condition-
ing paradigm was developed to examine how concurrent use 
of chlordiazepoxide with haloperidol or olanzapine might affect 
the induction and expression of antipsychotic sensitization in the 
conditioned avoidance response test (Li et al., 2009b). It was 
observed that pairing of chlordiazepoxide with haloperidol during 
the repeated drug test phase for seven days attenuated the anti-
avoidance effect of haloperidol, indicating an attenuation of the 
development of haloperidol sensitization. However, such pairing 
did not have a lasting effect on the expression of haloperidol sensi-
tization, as there was no group difference between the group that 
received the chlordiazepoxide+haloperidol pairing and those that 
received no such pairing in the haloperidol challenge test. In con-
trast, pairing of chlordiazepoxide with olanzapine had little effect 
on the induction of olanzapine sensitization, but did reduce its 
expression. This effect of chlordiazepoxide is due to drug-drug con-
ditioning, as the control groups that received the same treatment 
(i.e. chlordiazepoxide with haloperidol or olanzapine) but separated 
by 24 h did not show such an effect. These findings suggest that 
concurrent use of chlordiazepoxide with antipsychotics, especially 
with olanzapine, may cause a long-term attenuation of olanzapine 
sensitization through a drug-drug interaction mechanism.
Following a similar approach, a recent study examined how 
the antidepressant citalopram pairing with haloperidol or olan-
zapine during the induction phase affects antipsychotic sensitiza-
tion in the conditioned avoidance response model (Sparkman and 
Li, 2012). It was reported that concurrent use of citalopram with 
both antipsychotic drugs potentiated the anti-avoidance effect of 
olanzapine or haloperidol (to a lesser extent) during the seven 
drug test sessions, indicating that citalopram enhanced the devel-
opment of antipsychotic sensitization. However, in the subse-
quent challenge test, no group difference was found, suggesting 
that repeated pairing of citalopram with haloperidol or olanzap-
ine did not affect the expression of antipsychotic sensitization. 
These findings suggest that the presence of an antidepressant 
could potentially change the strength of antipsychotic sensitiza-
tion, and possibly the antipsychotic efficacy of haloperidol and 
olanzapine in the treatment of schizophrenia. Recently, we 
observed that concurrent nicotine treatment attenuated haloperi-
dol’s sensitized effect on avoidance response (unpublished obser-
vation). This finding also suggests that haloperidol sensitization 
might involve drug-induced changes in nicotinic receptor. It has 
been reported that haloperidol non-competitively inhibits the 
function of mammalian neuronal nicotinic α4β2 and α7 receptors 
with potencies comparable to that of mecamylamine (a classical 
nicotinic receptor antagonist) (Grinevich et al., 2009).
Nonpharmacological factors
Like behavioral sensitization and tolerance induced by other psy-
choactive drugs such as amphetamine (Browman et al., 1998) 
and morphine (Siegel, 1978), antipsychotic sensitization and 
tolerance are also greatly affected by nonpharmacological factors 
such as environmental stimuli, selected behavioral responses, 
behavioral testing contingencies, and passage of time, etc.. In the 
following, I will summarize some relevant work on this topic.
Environmental cues and selected behavioral responses. It is 
well established that the manifestations of behavioral sensitiza-
tion and tolerance induced by many psychoactive drugs are not 
mere consequences of the pharmacological actions of the drugs, 
but are the result of interactions amongst the pharmacological 
effects of drugs and the environmental cues during drug adminis-
tration. The importance of environmental factors in modulating 
antipsychotic sensitization and tolerance has been demonstrated 
by many investigators. The typical approach is to compare a 
“paired” group (a group that receives drug injection in the test 
environment) with an “unpaired” group (a group that receives 
vehicle injection in the test environment, and drug in the home 
cage) (Amtage and Schmidt, 2003; Poulos and Hinson, 1982). 
The influence of environment is assessed on a test day, when all 
animals receive a challenge injection of the drug in the test envi-
ronment. If a stronger or weaker drug effect is detected in the 
“paired” group, it would suggest that environmental stimuli have 
an influence on the drug effect (Robinson et al., 1998). Using 
such an approach, Poulos and Hinson (1982) demonstrated that 
Pavlovian conditioning factors determine the expression of toler-
ance to haloperidol catalepsy. They found that rats exhibited tol-
erance only in the environment previously associated with 
haloperidol injections, but not in the environment previously 
associated with saline injections. In addition, a drug-induced 
increase in the number of brain dopamine receptors, by itself, 
cannot account for the conditional occurrence of such tolerance. 
Schmidt’s group reported that intermittent haloperidol treatment 
and repeated catalepsy testing caused a sensitized cataleptic 
response over time and this sensitization was completely context 
specific, since context changes abolished catalepsy sensitization 
(Amtage and Schmidt, 2003; Klein and Schmidt, 2003). They 
reported that rats treated with haloperidol (0.25 mg/kg, i.p.) and 
tested over a nine-day period showed intensification of catalepsy. 
However, when the rats were tested in another environment, this 
change of the environmental context abolished the catalepsy sen-
sitization. In addition, they found that rats that were treated with 
haloperidol in the home cages but not repeatedly tested for cata-
lepsy also did not show catalepsy sensitization; often they devel-
oped tolerance towards the cataleptogenic effects of haloperidol 
(Schmidt et al., 1999). Similarly, sensitization induced by halo-
peridol and olanzapine in the conditioned avoidance response 
test was also context dependent, as only the rats treated with both 
drugs in the avoidance test apparatus and tested for avoidance 
responding exhibited such a sensitization; those that received the 
identical treatments in the home cages did not (Li et al., 2009b; 
Sparkman and Li, 2012).
Recently, a different approach was employed to examine the 
context-dependent sensitization and tolerance. It takes advantage 
of the fact that repeated antipsychotic treatment induces sensiti-
zation or tolerance in both the conditioned avoidance response 
and PCP-induced hyperlocomotion models, and sensitization or 
tolerance induced in these two models presumably reflects the 
same antipsychotic activity over time. If antipsychotic sensitiza-
tion or tolerance results from inevitable neurobiological adapta-
tions produced by the direct pharmacological actions of the drug 
(Tarsy and Baldessarini, 1974), it should be transferrable across 
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models and suggests that contextual and behavioral variables 
have little influence on the development of antipsychotic sensiti-
zation or tolerance. On the other hand, if context and behaviors 
associated with drug administration have a powerful control on 
the expression of antipsychotic sensitization or tolerance, it 
should not be transferrable between models. In the first study 
(Zhang and Li, 2012), we tested haloperidol and olanzapine sen-
sitizations and examined their bi-directional transfer between the 
conditioned avoidance response model and PCP model. Results 
showed that haloperidol and olanzapine sensitization induced in 
both models only manifested itself when the induction model 
was the same as the expression model. There was no expression 
of such a sensitization effect when the tested environment and 
required behavioral response were different from the original 
ones. These findings suggest the expression of haloperidol and 
olanzapine sensitization in the conditioned avoidance response 
model and PCP model is strongly influenced by test environment 
and/or selected behavioral response (Zhang and Li, 2012).
Feng et al. (2013) used a similar approach and examined how 
the environmental cues and behavioral responses affect the 
expression of clozapine tolerance. They found that when tested in 
the PCP model, rats previously treated with clozapine in the 
avoidance model did not show an immediate weaker inhibition of 
PCP-induced hyperlocomotion than those treated with clozapine 
for the first time, but showed a significantly weaker inhibition 
over time, suggesting that switching the environments dimin-
ished the initial expression of clozapine tolerance. In contrast, 
when tested in the avoidance response model, rats previously 
treated with clozapine in the PCP model showed an immediate 
weaker disruption of avoidance response than those treated with 
clozapine for the first time, but this weaker effect reduced over 
time. Therefore, similar to antipsychotic sensitization, the expres-
sion of clozapine tolerance is also strongly modulated by the test 
environment and/or selected behavioral response.
Because the context-dependent feature of antipsychotic sensi-
tization and tolerance resembles the one found in psychomotor 
sensitization (Anagnostaras and Robinson, 1996; Anagnostaras 
et al., 2002; Browman et al., 1998; Robinson et al., 1998; Stewart 
and Vezina, 1991, Vezina et al., 1989), and tolerance (Poulos 
et al., 1981; Siegel, 1978; Siegel et al., 2000), the theoretical con-
ceptualization of antipsychotic sensitization and its situational 
specificity can gain insights from the theoretical accounts of 
behavioral sensitization and tolerance. Based on the present 
study, our previous work (Li et al., 2004, Li et al., 2007, 2009a, 
2009b, 2010, Mead and Li, 2010) and the work of others 
(Anagnostaras et al., 2002; Stewart and Vezina, 1991), we pro-
pose that three psychological processes may govern the effect of 
antipsychotic sensitization or tolerance and its situational speci-
ficity (Zhang and Li, 2012): (a) repeated antipsychotic treatment 
induces an unconditioned and nonassociative increase or decrease 
of behavioral effects (i.e. sensitization); an effect attributable to the 
direct pharmacological action of a drug, likely mediated by drug-
induced time-dependent brain changes involving various receptors 
or other molecules that antipsychotic drugs target; (b) distinct con-
textual cues (e.g. environmental stimuli, interoceptive drug cue, 
etc.) develop an association with unconditional drug effects via a 
Pavlovian conditioning process and thus become excitatory condi-
tioned stimuli. These cues acquire the ability to elicit an antipsy-
chotic-like effect by themselves, and may potentiate the sensitized 
or diminished response in an expected situation; (c) situational 
cues, including the contextual stimuli, interoceptive drug state, as 
well as topographic difference in motor responses, serve as occa-
sion-setters to modulate the manifestation of altered responses. 
Occasion-setters are a class of conditional stimuli that do not them-
selves elicit an antipsychotic-like effect, but modulate the ability of 
other stimuli to elicit responses (Holland, 1989). According to this 
hypothesis, the same situational cue could function as both a drug-
like CS and an occasion-setter.
At last, we would to emphasize that there are not two forms 
of antipsychotic sensitization or tolerance: “context-specific” 
and “context-independent”, just as there are not two forms 
of behavioral sensitization induced by psychostimulants 
(Anagnostaras et al., 2002). There is just one non-associative 
form of neuroplasticity manifesting behaviorally as an alteration 
in antipsychotic responses. This manifestation and its modulation 
by environmental cues and behaviors is dependent on specific 
experimental and drug treatment factors. Only under certain cir-
cumstances do environmental cues or behavioral responses mod-
ulate the development and expression of antipsychotic 
sensitization or tolerance. Therefore, the environmental cues and 
behavioral responses of animals may not fundamentally alter 
drug-induced neurobiological changes, say, in D2 or 5-HT2A 
receptors. They only impact the functional manifestations of 
drug-induced brain changes. One recent study clearly illustrates 
this point because it demonstrates both the “context-dependent” 
and “context-independent” antipsychotic sensitization and toler-
ance for some drugs but not others and under one condition but 
not others (Sun et al., 2014). In the first experiment, which exam-
ined the extent to which prior antipsychotic treatment in the 
home cages affected a drug’s ability to inhibit PCP-induced 
hyperlocomotion in a novel motor activity test apparatus, it was 
shown that five days of repeated haloperidol and olanzapine 
treatment in the home cages still potentiated their inhibition of 
PCP-induced hyperlocomotion (i.e. the expression of antipsy-
chotic sensitization) assessed in a new environment, whereas the 
clozapine treatment enhanced the development of clozapine tol-
erance. These findings indicate a lack of environmental modula-
tion of antipsychotic efficacy, a finding different from Zhang and 
Li (2012) and Feng et al. (2013). The second experiment exam-
ined the impact of different numbers of antipsychotic administra-
tions in either the home environment or test environment (e.g. 4, 
2, or 0) on a drug’s ability to inhibit PCP-induced hyperlocomo-
tion. No environmental modulation was found for clozapine and 
olanzapine but a strong modulation was found for haloperidol, as 
evidenced by the finding that four-day haloperidol treatment in 
the test apparatus had a significantly higher inhibition than four-
day home cage treatment. These findings collectively suggest 
that prior antipsychotic treatment in one environment could alter 
later antipsychotic-like response assessed in a different environ-
ment but only under certain test conditions. Therefore, whether 
the circumstances surrounding antipsychotic drug administration 
exert a powerful control of the expression of antipsychotic-like 
efficacy is dependent on many factors, including the degree of 
similarity between different test environments, drug doses, and 
number of drug treatments, etc. The environmental modulation 
on antipsychotic sensitization and tolerance may have a signifi-
cant clinical implication. For one thing, it suggests that the envi-
ronment where the drug is being administered could potentially 
change how a patient responds to the drug.
Passage of time (i.e. test interval between the induction 
and expression phase). Antipsychotic sensitization and 
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tolerance likely reflect a composite impact from two sources. 
One is the relatively specific pharmacological actions of a given 
antipsychotic drug. As mentioned before, this is likely mediated 
by a drug’s actions on its immediate neuroreceptor targets (e.g. 
D2 and 5-HT2A receptors) (Li et al., 2010) and should follow the 
basic principles of learning and memory, as antipsychotic sensiti-
zation and tolerance represent a non-associative form of learning 
and memory. Under this principle, the magnitude of sensitization 
and tolerance should decrease with the passage of time due to a 
memory trace decay process (similar to forgetting). Another 
source is the ubiquitous adaptive response to the foreign aspect of 
the drug (any drug is an exogenous agent to an organism), which 
tends to follow the TDS principle (Antelman et al., 1986, 2000) 
and this response should increase with the passage of time upon 
acute exposure to the drug. Therefore, under one circumstance, 
we may see an increase of antipsychotic sensitization and toler-
ance when the experimental condition favors the TDS principle, 
whereas under other circumstances, the sensitization and toler-
ance effect may decrease when the forgetting force dominates. 
The ultimate intensity of antipsychotic sensitization or tolerance 
at any given time point likely reflects the consequence of a joint 
action from these two forces. An earlier study did not find that the 
magnitude of haloperidol and olanzapine sensitization in the con-
ditioned avoidance response test changed across the three time 
intervals between the induction and expression phases (i.e. 4, 10, 
or 17 days after the last drug treatment) (Swalve and Li, 2012). 
Recently, this issue was re-examined using 3 longer intervals (10, 
20 and 40 days between the last drug treatment and challenge 
test) (Gao and Li, 2013). Once again, no increase or decrease in 
sensitization magnitude was observed at these test points. Thus, 
although theoretically, antipsychotic sensitization and tolerance 
could be a function of time, empirical evidence is lacking. Future 
research needs to examine the importance of different challenge 
doses and numbers of drug administration to determine the 
experimental conditions that favor TDS as it relates to antipsy-
chotic sensitization and tolerance. In this regard, it appears that 
one single injection of haloperidol is able to induce a sensitiza-
tion effect in the PCP-induced hyperlocomotion test and this 
effect is larger when assessed at the three-week post-injection 
point than at one-week post-injection (unpublished observation). 
We are actively pursuing this line of research to verify its robust-
ness and its generality. It is also important to keep in mind that 
because environmental stimuli and behavioral response have a 
profound impact on the induction and expression of antipsy-
chotic sensitization and tolerance (see the above discussion), in 
searching for the optimal condition that is conducive to TDS, we 
should pay more attention to the environmental cues and behav-
ioral responses that are associated with drug administration.
Developmental impacts: Altered drug 
sensitivity due to adolescent drug exposure
Antipsychotic treatment in children and adolescents has 
increased dramatically in recent decades (Kalverdijk et al., 
2008; Olfson et al., 2006; Rani et al., 2008). Epidemiological 
surveys conducted in many countries (e.g. UK, US, Germany, 
Netherlands) indicate a two- to six-fold increase in the number 
of prescribed antipsychotics for young patients (⩽20 years) 
between the 1990s and the mid-2000s (Kalverdijk et al., 2008; 
Olfson et al., 2006; Rani et al., 2008). More than 90% of the 
children and adolescents who are treated with antipsychotic 
medications are on atypical drugs (e.g. risperidone, olanzapine, 
and aripiprazole) for the management of disruptive behavior dis-
orders (37.8%), mood disorders (31.8%), pervasive develop-
mental disorders, or mental retardation (17.3%) and psychotic 
disorders (14.2%) (Olfson et al., 2006). Clinical research on 
antipsychotic treatment in children and adolescents primarily 
focuses on the efficacy, tolerability, and side effect profiles of 
individual drugs. There is a general lack of research on the long-
term consequences of adolescent antipsychotic treatment on the 
brain and the behavioral development of patients.
Preclinical studies strongly suggest that antipsychotic expo-
sure in adolescence could alter brain and behavioral functions. 
For example, animal receptor binding studies show that antipsy-
chotic exposure during adolescence increases or decreases vari-
ous neuroreceptors, including dopamine D1, D2, and D4 receptors 
(Moran-Gates et al., 2006; Vinish et al., 2013), serotonin 5-HT1A 
and 5-HT2A receptors (Choi et al., 2010), and ionotropic NMDA 
and AMPA glutamatergic receptors (Choi et al., 2009). 
Behavioral studies also suggest that early adolescent antipsy-
chotic exposure enhances animals’ sensitivity to reward stimuli 
(Vinish et al., 2013), impairs their working memory, delays the 
extinction process of fear memory in adulthood (Milstein et al., 
2013), and prevents the development of various psychosis-like 
behaviors (e.g. prepulse inhibition (PPI) deficit, latent inhibition 
deficit, etc.) induced by maternal immune activation (PolyI:C 
injection during pregnancy), while impairing certain behavioral 
functions of normal animals (Meyer et al., 2010; Piontkewitz 
et al., 2009, 2011, 2012).
In addition to the effects on basic brain and behavioral func-
tions, adolescent antipsychotic exposure can also alter later 
antipsychotic responses in adulthood. Since 2012, we have con-
ducted a series of experiments and delineated the extent to which 
antipsychotic exposure during adolescence affects ‘exposure-
dependent’ alterations. Similar to what has been reported in 
adult animal studies, two patterns of alterations: sensitization 
and tolerance are also identified. The first study used the condi-
tioned avoidance response model and addressed two important 
issues: first, whether olanzapine sensitization and clozapine tol-
erance can be induced in adolescent rats; second, the extent to 
which olanzapine sensitization and clozapine tolerance induced 
in adolescence persist into adulthood (Qiao et al., 2013). The 
basic paradigm is similar to that depicted in Figure 1. Male ado-
lescent rats (~postnatal days (P) 43–47) were first treated with 
olanzapine or clozapine daily for five consecutive days and then 
challenged either in adolescence (~P 50) or after they matured 
into adults (~P 76 and 92). Olanzapine sensitization and clozap-
ine tolerance were found in the behavioral measures of antipsy-
chotic activity (e.g. avoidance response and intertrial crossing), 
but not in the measure of fear (e.g. CS-induced 22 kHz ultra-
sonic vocalizations (USVs)) (Mead et al., 2008; Sun et al., 
2010). These findings suggest that antipsychotic treatment dur-
ing adolescence can induce a long-term specific alteration in 
antipsychotic effect that persists into adulthood despite the brain 
maturation. Both olanzapine sensitization and clozapine toler-
ance effects are dose-dependent, specific to the antipsychotic 
effect (e.g. anti-avoidance), but not to the anxiolytic effect (e.g. 
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a decreasing effect on 22-kHz USVs). These results also support 
the idea that the different behavioral effects of an antipsychotic 
drug undergo different time courses of change after repeated 
administration (Stewart and Badiani, 1993).
Following this initial study, a series of studies have been con-
ducted on other antipsychotic drugs. Risperidone, asenapine, and 
haloperidol are all found to cause a sensitization effect that per-
sists into adulthood in a similar fashion as olanzapine in the con-
ditioned avoidance response model (Gao and Li, 2014; Qiao 
et al., 2014b; Shu et al., 2014a) (see Figure 5). In addition, 
adolescent risperidone treatment could even alter adulthood 
responsiveness to olanzapine (a cross-sensitization effect) and 
clozapine (Qiao et al., 2014b). Specifically, evidence indicates that 
adolescent risperidone treatment essentially enhances olanzapine 
sensitization and clozapine tolerance. These long-lasting changes 
are likely mediated by drug-induced neuroplastic changes and 
could have significant clinical implications because risperidone 
has been one of the most prescribed antipsychotic agents for 
children and adolescents (Patel et al., 2005) and drug switching 
is quite common in people with schizophrenia during the course 
of optimizing therapeutic regimens for individual patients 
(Rosenheck et al., 2009). These findings suggest that the past his-
tory of a patient’s experience with a given drug may impact his/
her later response to a new drug. Thus, clinicians working with 
adult patients who have been treated with one drug (e.g. risperi-
done) but wish to switch to another drug (e.g. olanzapine or clo-
zapine) may need to consider possible changes in antipsychotic 
efficacy and monitor patients’ symptom response to the new drug 
during this switching process.
In order to validate the generality of adolescent antipsychotic 
sensitization and clozapine tolerance effects, it is necessary to 
employ a similar test paradigm used in one test (e.g., the condi-
tioned avoidance response model) and apply it in another (e.g. 
PCP-induced hyperlocomotion model). Shu et al. (2014a) did just 
that (see Figure 6). This study showed that during adolescence, 
repeated olanzapine or clozapine treatment produced a persistent 
inhibition of PCP-induced hyperlocomotion across the five test 
days. In the challenge test during adolescence, rats previously 
treated with olanzapine did not show a significantly stronger 
inhibition of PCP-induced hyperlocomotion than those previ-
ously treated with vehicle. In contrast, those previously treated 
with clozapine showed a weaker inhibition than the vehicle con-
trols. When assessed in adulthood, the enhanced sensitivity to 
olanzapine and the decreased sensitivity to clozapine were 
detected on ~P 76, even on ~P 91 in the case of olanzapine. These 
findings suggest that adolescent olanzapine or clozapine expo-
sure can induce long-term alterations in antipsychotic response 
that persist into adulthood. A subsequent study demonstrated that 
repeated risperidone treatment in adolescence could also cause a 
sensitization effect in this model of antipsychotic activity (Qiao 
et al., 2014a).
Much of our adolescent antipsychotic sensitization and toler-
ance work has relied on a daily intermittent drug injection sched-
ule for a short period of time (e.g. five days). How these long-term 
effects are modulated by treatment schedule has never been 
examined. In a recent study (Gao and Li, 2014), we explored how 
haloperidol sensitization induced throughout adolescence and 
tested in adulthood was differentially impacted by these two dos-
ing regimens in the conditioned avoidance response test (Figure 
7). Adolescent rats were treated with haloperidol continuously 
(via osmotic minipump) or intermittently (via daily injection) 
from P 44 to 71. Haloperidol sensitization was assessed in a chal-
lenge test in adulthood (>P 80) in which all rats were injected 
with haloperidol. Interestingly, only the intermittent dosing group 
showed a robust sensitization effect. This finding suggests that 
adolescent haloperidol sensitization is a schedule-specific phe-
nomenon, much like what we observe in other behavioral effects 
of antipsychotic drugs (Samaha et al., 2008; Turrone et al., 2005). 
It is more likely to be seen under an intermittent dosing regimen 
than under a continuous dosing one.
Recently, we showed that persistent aripiprazole sensitization 
from adolescence to adulthood is sex-dependent (unpublished 
observation). In both the induction phase and the expression 
phase, male rats always had significantly lower avoidance than 
the females under aripiprazole, indicating that male rats might be 
more sensitive to aripiprazole treatment. This result suggests that 
Figure 5. Repeated asenapine (ASE) treatment increased the suppression of avoidance response in adolescent rats (postnatal days, P 43–48) (a) 
and increased sensitivity to ASE re-exposure in the challenge test in adulthood (P ~76) (b). Number of avoidance responses made by the rats from 
the ASE (0.05 mg/kg), ASE (0.10 mg/kg), ASE (0.20 mg/kg) and vehicle groups on the last training (pre-drug) day, during the five drug test days 
and on the challenge test day are expressed as mean+standard error of the mean (SEM). **p<0.004, three ASE groups relative to the VEH group; 
#p<0.05, ASE 0.10 and ASE 0.20 groups relative to the ASE 0.05 group, respectively. Adapted from Shu Q, Qin R, Chen Y, et al. (2014b) Asenapine 
sensitization from adolescence to adulthood and its potential molecular basis. Behav Brain Res 273: 166–176 with permission from Elsevier. 
VEH: vehicle.
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antipsychotic sensitization might vary between sexes and clearly 
has a significant clinical implication if replicated.
As discussed at the beginning of this section, adolescent antip-
sychotic treatment is known to exert long-term impacts of basic 
behavioral and brain functions. However, no studies have exam-
ined whether adolescent antipsychotic treatment would affect 
social functioning in adulthood, one of seven primary cognitive 
domains that are affected in schizophrenia (Floresco et al., 2005; 
Green et al., 2004,). Gao and Li (2014) examined how intermit-
tent and continuous haloperidol treatment may potentially impact 
social interaction and social memory using a paradigm that we 
validated in amphetamine and phencyclidine-based animal mod-
els of schizophrenia (Li et al., 2012). The social memory of rats 
was evidenced by the findings that a subject rat decreased its time 
investigating the same testing partner after a waiting period (~10 
min) and increased its time on investigation if a novel partner was 
Figure 6. Olanzapine (OLZ) sensitization from adolescence to adulthood. Locomotor activity was measured during the 60-minute test period after 
daily PCP injection throughout the five test days (left) and during the OLZ challenge test on postnatal day (P) 76 (right). OLZ at 1.0 and 2.0 mg/
kg induced a sensitization effect in adulthood. Adapted from Shu Q, Hu G and Li M (2014a) Adult response to olanzapine or clozapine treatment is 
altered by adolescent antipsychotic exposure: A preclinical test in the phencyclidine hyperlocomotion model. J Psychopharmacol 28: 363–375. 
VEH: vehicle; PCP: phencyclidine.
Figure 7. Effects of chronic continuous versus intermittent haloperidol (HAL) treatment on conditioned avoidance responding over time. (a) Number 
of avoidance responses made by the rats treated with HAL-0.25 CONT (0.25 mg/kg/day via minipump, n=14), HAL-0.05 INT (0.05 mg/kg/injection/
day sc, n=14) or vehicle (VEH, n=13) on the predrug (0) day, and drug test days. ***p<0.001 for comparisons between HAL-(0.05 INT and 0.25 CONT) 
and vehicle (VEH); ###p<0.001, ##p<0.01, #p<0.05 for comparisons between HAL-0.05 INT and HAL-0.25 CONT on each test day. (b) Number of 
avoidance responses made by the three groups of rats in the HAL 0.05 mg/kg challenge tests. After retraining, all groups were injected with HAL 0.05 
mg/kg (sc) 11 days after the last HAL treatment. Avoidance tests were conducted 60 min later. All data are expressed as mean+standard error of the 
mean (SEM). **p<0.01 for comparison to the VEH group; ##p<0.01 for comparison to the HAL-0.05 INT group. Adapted from Gao J and Li M (2014) 
Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in 
adulthood. Prog Neuropsychopharmacol Biol Psychiatry 54: 67–75 with permission from Elsevier. 
CONT: continuous; INT: intermittent.
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introduced (Akers et al., 2006; Holloway and Thor, 1988; Prediger 
et al., 2004,). Our results show that adolescent haloperidol treat-
ment (continuous and intermittent) did not affect social behavior 
and social memory, as rats from the two haloperidol groups and 
the vehicle group exhibited a similar level of social interaction 
and showed a similar level of sensitivity to the change of social 
stimuli. This finding suggests that adolescent haloperidol treat-
ment under both regimens did not fundamentally damage social 
functioning. Thus, the clinical significance of haloperidol sensiti-
zation needs to be further examined.
Collectively, these important findings firmly establish that 
antipsychotic treatment in adolescence can induce a long-term 
change in drug responsiveness that persists into adulthood. This 
altered sensitivity appears to be sex- and regimen-specific. 
Because antipsychotic drugs are being increasingly used in chil-
dren and adolescents in the past two decades, findings from this 
study are important for understanding the impacts of adolescent 
antipsychotic treatment on the brain and behavioral develop-
ments. Furthermore, although we have demonstrated that environ-
mental stimuli and behavioral response associated with drug 
treatment have a profound impact on the induction and expression 
of antipsychotic sensitization and tolerance in adult animals (Feng 
et al., 2013; Sun et al., 2014; Zhang and Li, 2012), there is no 
study that has examined how such factors could affect adolescent 
antipsychotic sensitization and tolerance. Given their potential 
effects on brain development, if we can identify the clinical and 
experimental conditions that modulate adolescent antipsychotic 
sensitization and tolerance, we could then better use them to our 
advantages. This work also has implications for clinical practice 
involving adolescent antipsychotic treatments in terms of drug 
choice, drug dose, and schedule, and treatment setting.
Neurobiological mechanisms
Although behavioral sensitization and tolerance induced by 
antipsychotic drugs are well established, the molecular mecha-
nisms (e.g. receptor, intracellular signaling molecules) and neural 
basis of these effects are less clear. Given the fact that all antipsy-
chotic drugs have immediate actions on dopamine D2 and 5-HT2A 
receptors (Meltzer et al., 1989; Meltzer et al., 2003; Miyamoto 
et al., 2005), and repeated antipsychotic treatment induces long-
term changes in these receptors (Tarazi et al., 2001), one natu-
rally suspects that changes in these receptors may account for the 
behavioral sensitization and tolerance induced by antipsychotic 
drugs. As the following results may show, antipsychotic-induced 
changes in D2 and 5-HT2A receptors in the various limbic areas 
are indeed in part involved in the mediation of the induction and/
or expression of antipsychotic sensitization or tolerance. It should 
be noted that because many antipsychotics also have various 
degrees of affinity for a number of other neuronal receptors, 
including α-adrenergic, histamine H1, serotonin 5-HT1A, 5-HT6 
and 5-HT7 receptors, and muscarinic receptors, and this multi-
receptor action is likely to affect their efficacy and side effect 
profile (Lieberman et al., 2008), the magnitude and persistence 
of antipsychotic sensitization and tolerance might also be, to 
some extent, modulated by these receptor-binding affinities. 
Unfortunately, there is little research on the involvement of 
receptors other than D2 and 5-HT2A in antipsychotic sensitization 
and tolerance. Therefore, on the receptor mechanisms, we will 
have to limit ourselves to these two receptors.
Pharmacological studies on dopamine D2 and 
5-HT2A receptor mechanisms
Li et al. (2012) took a pharmacological approach and compared 
the neuroreceptor mechanisms underlying acute and repeated 
treatment effects of haloperidol, clozapine, or olanzapine treat-
ment, respectively. Specifically, they gave rats three days of 
repeated drug treatment and tested them in the conditioned avoid-
ance response model. For some drug-treated rats, they were 
also concurrently administrated with either saline, quinpirole 
(a selective dopamine D2/3 agonist,), or 2,5-dimethoxy-4-iodo-
amphetamine (DOI, a selective 5-HT2A/2C agonist). After two 
days drug-free retraining, a drug challenge test was conducted to 
examine the magnitude of haloperidol/olanzapine sensitization 
and clozapine tolerance. A previous study already shows that 
acute pretreatment of quinpirole, but not DOI, can dose-depend-
ently reverse the haloperidol-induced disruption of active mater-
nal responses, whereas acute pretreatment of DOI, but not 
quinpirole can reverse the disruption induced by clozapine (Zhao 
and Li, 2009a). Based on these findings and the receptor binding 
profiles of each antipsychotic (Miyamoto et al., 2005), it was 
hypothesized that acute and repeated effects of haloperidol may 
be mediated by its action on D2/3 receptor system, whereas those 
of olanzapine and clozapine may be mediated by their action on 
5-HT2A/2C receptors. If this hypothesis were correct, quinpirole, 
but not DOI, should be able to attenuate acute haloperidol-
induced disruption of avoidance response, and may also be effec-
tive in reducing haloperidol sensitization. In contrast, DOI, but 
not quinpirole, is expected to attenuate acute clozapine-induced 
disruption of avoidance, and may also be effective in reducing 
clozapine tolerance. For olanzapine, both quinpirole and DOI 
might have a reversal effect on its acute and repeated effects. This 
hypothesis was only partially confirmed. Specifically, pretreat-
ment of quinpirole, but not DOI, did attenuate the acute haloper-
idol-induced disruption of avoidance responding and to a lesser 
extent, olanzapine-induced disruption. In contrast, pretreatment 
of DOI, but not quinpirole, attenuated the acute effect of clozap-
ine. However, on the sensitization or tolerance effect, two unex-
pected findings were obtained. First, pretreatment of DOI, but 
not quinpirole, attenuated the haloperidol sensitization. Second, 
pretreatment of quinpirole enhanced the tolerance-like effect of 
clozapine and attenuated olanzapine sensitization. These results 
indicate that haloperidol sensitization may be mediated by its 
action on 5-HT2A/2C receptor system, whereas long-term effects 
of olanzapine and clozapine may be mediated by their action on 
the D2/3 receptor system. Although haloperidol is typically 
viewed as a strong D2 antagonist, it is also a 5-HT2A receptor 
inverse agonist (Weiner et al., 2001), and repeated haloperidol 
treatment causes a reduction in 5-HT2A receptor mRNA expres-
sion in various limbic regions (Buckland et al., 1997). Therefore, 
it is possible that haloperidol causes a sensitization effect by 
down-regulating 5-HT2A receptor. DOI may decrease this long-
term impact of haloperidol by counteracting its effect on 5-HT2A 
receptor. This idea is also consistent with the well-known aug-
mentation effect of 5-HT2A antagonism on the effects of haloperi-
dol, as 5-HT2A-selective antagonist M100907 is shown to 
potentiate haloperidol-induced dopamine release in the medial 
prefrontal cortex (Bonaccorso et al., 2002), to reduce the reward-
attenuating effect of haloperidol (Benaliouad et al., 2007), and to 
potentiate the avoidance disruptive effect of haloperidol 
(Wadenberg et al., 2001). The clozapine tolerance and olanzapine 
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sensitization via D2/3 receptor systems could be understood in the 
context of their known long-term effect on D2/3 receptors (Atkins 
et al., 1999; Kapur et al., 2003; Moran-Gates et al., 2006). But 
why activation of D2/3 receptors reduces olanzapine sensitization 
but potentiates clozapine tolerance is not clear. One important 
lesson from this study is that the neuroreceptor mechanisms 
underlying the acute effect of an antipsychotic drug could be dis-
sociable from those underlying its long-term effect. Thus, for the 
long-term effects such as sensitization and tolerance, the drug-
initiated neural plasticity plays a more important role than the 
immediate targets of a drug.
Behavioral studies on dopamine D2 receptor 
mechanism
Although we failed to show the involvement of D2 receptor in 
haloperidol sensitization, given its well characterized antagonism 
of D2 receptors, it seems premature to discount the role of this 
receptor system in the mediation of antipsychotic sensitization 
in general. Gao and Li (2013) used the quinpirole-induced hyper-
locomotion test and further investigated the involvement of D2 
receptor in antipsychotic sensitization. This test is a widely used 
method assessing drug or non-drug induced changes in D2 func-
tion (Tenk et al., 2007; Vorhees et al., 2009). Because quinpirole 
is a preferential D2/3 receptor agonist, and its psychomotor stimu-
lating effect (i.e. increasing locomotor activity) is generally attrib-
uted to its selective agonism on D2, if a drug-treated rat shows a 
higher level of motor activity under quinpirole challenge than a 
vehicle-treated one, it would suggest that the drug causes an 
upregulation of D2 receptor (Luque-Rojas et al., 2013; Moreno 
et al., 2005). Indeed, this quinpirole-induced hyperlocomotion has 
been thought to be mediated through an increase in the efficacy of 
the post-synaptic D2 transduction (Szumlinski et al., 1997, 2000). 
Gao and Li (2013) observed that prior risperidone-treated adult 
rats showed a sensitization effect in the conditioned avoidance 
response test. Also, they exhibited a significantly higher level of 
motor activity than the vehicle-pretreated ones when they were all 
challenged with quinpirole, suggesting that risperidone sensitiza-
tion is likely mediated by D2 receptor supersensitivity (Seeman, 
2011). A more recent study from our laboratory showed that ari-
piprazole-induced sensitization in adult rats is also mediated by 
drug-induced upregulation of D2 receptor (Gao et al., 2015). 
However, antipsychotic sensitization induced during adolescence 
seems less dependent on D2 receptor upregulation, as adult rats 
that had been treated with risperidone or haloperidol in adoles-
cence failed to show an increased motor activity under the quin-
pirole challenge, despite the fact that they exhibited a robust 
sensitization effect (Gao and Li, 2014; Qiao et al., 2014a). This 
finding highlights that antipsychotic treatment during the adoles-
cent period may alter D2 receptors and others (e.g., 5-HT2A, 
5-HT2B and 5-HT1A) in unique ways not seen in adult animals. 
Thus, adolescent antipsychotic sensitization (or tolerance) may 
rely on different receptor mechanisms than adulthood sensitiza-
tion. This is because various neurotransmitter systems — espe-
cially the dopamine and serotonin systems in the prefrontal cortex, 
striatum, and hippocampus — are still undergoing maturational 
changes during adolescence (Benes et al., 2000; Teicher et al., 
1995). At the present time, available evidence indicates that 
antipsychotic sensitization induced by olanzapine, risperidone 
and aripiprazole is likely mediated by D2 receptor upregulation, at 
least in adult rats. The 5-HT2A receptors may also play an 
important role in this effect as seen in haloperidol sensitization. 
Clearly, more work is needed to delineate the neuroreceptor 
mechanisms of antipsychotic sensitization and tolerance.
c-Fos immunocytochemistry study of the 
neural basis of antipsychotic sensitization
c-Fos, a protein product of immediate-early gene c-fos has been 
used as a molecular biomarker for identifying the neural basis of 
acute antipsychotic treatment (Robertson and Fibiger, 1992; 
Robertson et al., 1994). Acute administration of typical antipsy-
chotic haloperidol and atypical drug clozapine produces a different 
induction pattern of c-Fos expression in the forebrain, with acute 
haloperidol increasing c-Fos-positive neurons in the dorsolateral 
striatum (DLSt), nucleus accumbens shell (NAs) and core (NAc), 
and lateral septal nucleus (LS) and acute clozapine producing such 
effects in the NAs, medial prefrontal cortex (mPFC) (Robertson 
and Fibiger, 1992; Robertson et al., 1994). Based on these obser-
vations, we postulated that by examining how repeated antipsy-
chotic treatment alters c-Fos expression, we may be able to identify 
the neuroanatomical bases of antipsychotic sensitization or toler-
ance. In one study (Zhao et al., 2012), the c-Fos expression in the 
PCP-induced hyperlocomotion model was examined. Once daily for 
five days, adult male rats were injected with haloperidol, clozapine 
or saline, followed by an injection of PCP or saline 30 min later, and 
motor activity was measured for 90 min after PCP injection. c-Fos 
immunoreactivity was assessed either after acute (day 1) or repeated 
(day 5) haloperidol or clozapine tests. Based on the changes of c-Fos 
expression, a brain region had to meet the following three criteria in 
order to be considered as part of the neural circuit(s) by which halo-
peridol and clozapine act to achieve their sensitization or tolerance 
effect, respectively. First, it should show altered c-Fos expression in 
response to both acute and repeated treatment of PCP. Second, it 
should show altered PCP-induced c-Fos expression in response to 
acute and repeated treatment with haloperidol or clozapine. Third, it 
should show a change in c-Fos expression from day 1 to day 5. 
Based on these criteria, three regions including NAs, central amyg-
dala (CeA) and VTA could be classified as part of the haloperidol 
neural circuit (likely mediating haloperidol sensitization), and three 
regions including mPFC, ventral part of lateral septal nucleus (LSv) 
and VTA as part of the clozapine neural circuit (likely mediating 
clozapine tolerance). It should be pointed out that while c-Fos is an 
important step in illuminating the differences in neuronal actions 
between haloperidol and clozapine in this task, these data should 
be regarded as one piece of evidence toward delineating the neural 
basis of these drug effects. Thus, other indices such as neurotrans-
mitter release, receptor density changes should be used to validate 
the current findings in future work.
Central microinjection studies on dopamine 
D2 and 5-HT2A mechanisms
Previous studies indicate that down-regulation of 5-HT2A receptors 
is one of the mechanisms underlying the therapeutic effects of 
chronic treatment with antipsychotic drugs (Moreno et al., 2013). 
Furthermore, our own c-Fos study suggested that the mPFC is part 
of the neural circuit that mediates the repeated effect of clozapine, 
e.g. clozapine tolerance. Therefore, it is possible that 5-HT2A 
receptors in the mPFC might be one of the central receptor mecha-
nisms of clozapine tolerance. We are aware of only one study that 
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tested this hypothesis in the CAR model (Feng et al., 2015). In this 
microinjection study, adult male rats were first trained in the avoid-
ance test and then repeatedly injected with vehicle or clozapine for 
five days; their avoidance response was tested daily. Fifteen min-
utes before each daily test, they were also centrally infused with 
selective 5-HT2A/2C agonist DOI at 0.0, 5.0, or 25.0 µg/0.5 µL/side 
into the mPFC. It was shown that intra-mPFC infusions of DOI 
had no effect on the acute avoidance-disruptive effect of clozapine 
throughout the five test days. One day after the 5th clozapine test, 
all rats were retrained drug-free to bring their avoidance back to 
the pre-drug level before the final challenge test to assess the 
expression of clozapine tolerance. In the challenge test, we found 
that rats centrally infused with DOI 25.0 µg/0.5 µL/side during the 
repeated clozapine treatment days did not show higher avoidance 
than their corresponding vehicle controls, indicating an absence of 
clozapine tolerance. In other words, activation of 5–HT2A/2C sero-
tonergic receptors in the mPFC by DOI did not affect the acute 
effect of clozapine, but only abolished clozapine tolerance, sug-
gesting clozapine tolerance is mediated by 5–HT2A/2C receptors in 
the mPFC. This notion is supported by the subsequent experiment 
in which we centrally injected DOI 25.0 µg/0.5 µL/side immedi-
ately prior to the challenge test. We found that the intra-mPFC 
infusion of DOI at 25.0 µg/0.5 µL/side prior to the challenge test 
blocked the expression of clozapine tolerance. Thus, findings from 
this study confirmed that the mPFC is one critical brain region 
where clozapine acts to achieve its behavioral effects. It also sug-
gests that the expression of clozapine tolerance, but not the toler-
ance induction is dependent on 5-HT2A/2C receptors in the mPFC.
Possible intracellular mechanisms
Different classes of clinically effective antipsychotics all share a 
common molecular mechanism involving inhibition of D2/β-
arrestin-mediated signaling (Li et al., 2007; Masri et al., 2008). 
GSK3β is a key substrate of the dopamine-mediated β-arrestin/
Akt signaling pathway and plays a critical role in neuronal devel-
opment and function, including neurogenesis, axon/dendrite dif-
ferentiation, neuronal positioning, synaptic transmission and 
plasticity, and neural apoptosis (Kaidanovich-Beilin et al., 2012; 
Kim and Snider, 2011). Dysregulation of this enzyme activity 
(e.g. reduced GSK3β protein levels in the prefrontal cortex) has 
been reported in patients with schizophrenia and mood disorders 
and in animal models of these mental disorders (Kozlovsky et al., 
2005; Nadri et al., 2003). Antipsychotic drugs are demonstrated 
to cause an increase in the phosphorylation of GSK3β and con-
comitant inhibition of GSK3β activity via antagonizing D2 and 
5-HT2A, and this GSK3β action is thought to mediate the thera-
peutic effects of antipsychotic treatment (Beaulieu et al., 2007; 
Freyberg et al., 2010; Karam et al., 2010; Li et al., 2007). More 
importantly, such regulation of GSK3β activity has been reported 
after chronic treatment with antipsychotic drugs, leading us to 
speculate that inhibition of GSK3β activity by antipsychotic 
treatment might be one of the mechanisms leading to persistent 
antipsychotic sensitization from adolescence to adulthood. If this 
hypothesis were correct, we would expect that (a) antipsychotic 
treatment would cause a persistent decrease in GSK3β activity 
(increased phospho-GSK3β); and (b) increasing GSK3β activity 
would attenuate the antipsychotic sensitization effect induced in 
both adolescence and adulthood. We recently obtained promising 
preliminary data consistent with the first expected result. Rats 
that showed a persistent olanzapine sensitization from 
adolescence to adulthood had higher levels of p-Akt and 
p-GSK3β, suggesting that the elevated p-Akt and p-GSK3β may 
be responsible for this long-lasting effect. Future systemic work 
needs to further test this hypothesis and determines whether ele-
vated p-Akt and p-GSK3β is responsible for the long-lasting 
antipsychotic sensitization and tolerance in general.
Summary and future research
It is well documented now that antipsychotic drugs are exoge-
nous stimuli that impact the brain and cause long-term behavioral 
changes and associated neuroadaptations. Behaviorally, antip-
sychotic-induced changes reflect an increase (sensitization) or 
decrease (tolerance) in drug sensitivity and environmental cues 
and behavioral response associated with drug treatment have a 
profound impact on the induction and expression of antipsy-
chotic sensitization and tolerance. Neurochemically, dopamine 
D2 and serotonin 5-HT2A receptors play a role in these two behav-
ioral effects of antipsychotic treatment. Neuroanatomically, the 
mPFC-related neural circuitry is critically involved in the clozap-
ine tolerance, while other regions (e.g. NAs, VTA, and CeA) may 
be involved in the mediation of antipsychotic sensitization.
The present paper reviews some of the important evidence in 
the literature, focusing on the drug-induced changes in antipsy-
chotic response. It is fair to say that although the research commu-
nity of antipsychotic drugs is relatively large and highly active, this 
particular field (i.e. research on antipsychotic sensitization and 
tolerance) is rather small, and much of the work comes from a 
limited number of laboratories and uses a limited number of ani-
mal models (e.g. conditioned avoidance, PCP-induced hyperloco-
motion, etc.). Therefore, it is imperative for future research to raise 
the profile of this area by focusing several areas, as outlined below.
One major area of research is to determine the clinical rele-
vance of antipsychotic sensitization and tolerance. Are they clini-
cally relevant for the explanation of the clinical effects (both 
therapeutic and side effects) of antipsychotic treatment? What 
clinical effect could be explained by sensitization and what could 
be explained by tolerance? What pharmacological features 
account for the differences between sensitization and tolerance? 
Why does clozapine primarily cause a tolerance in several behav-
ioral tests of antipsychotic activity, while others induce a sensiti-
zation? Could this difference explain the superior treatment 
effect of clozapine? etc. What clinical phenomena are associated 
with clozapine tolerance? Clinician scientists could help answer 
these questions by looking into these two mechanisms as explan-
atory tools. At this time, it is fair to say that preclinical findings 
on antipsychotic sensitization and tolerance have not made a 
good connection with clinical research. Thus basic psychophar-
macologists also need to understand clinical phenomena better.
As mentioned, antipsychotic sensitization and tolerance have 
not been systematically studied in a preclinical disease model of 
schizophrenia. All the published work so far has been done in 
otherwise healthy male rats. Therefore, the face validity is low as 
only humans with severe mental disorders such as schizophrenia 
receive antipsychotic therapy. Animal work also suggests that 
antipsychotic treatment has differential effects on “diseased” 
rodents and normal controls (Meyer et al., 2010). Thus, one 
important future focus for basic scientists is to examine antipsy-
chotic sensitization and tolerance in animal models of schizo-
phrenia. Resolving this issue could also help determine the 
clinical significance of antipsychotic sensitization and tolerance.
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To date, limited research is available on the effects of adoles-
cent antipsychotic exposure on basic psychological functions such 
as attention, novelty-seeking, emotion, and learning and memory 
(Milstein et al., 2013; Vinish et al., 2013). How antipsychotic sen-
sitization and tolerance contribute to these effects has never been 
explored. Furthermore, whether functional changes in D2 and 
5-HT2A receptor expressions induced by adolescent antipsychotic 
treatment are related to drug-induced behavioral effects has not 
been examined. Future research should fill these knowledge gaps 
by connecting what we know about the basic behavioral effects of 
adolescent antipsychotic treatment with the treatment’s intrinsic 
property of altering drug sensitivity. This research will signifi-
cantly enhance our understanding of the positive and negative 
impacts of adolescent antipsychotic treatment on drug response, 
behavioral functions, and brain functions.
Another important research area is to identify the neural 
mechanisms of antipsychotic sensitization and tolerance. 
Because antipsychotic drugs have a profound impact on a vari-
ety of brain signaling molecules involved in a variety of impor-
tant yet different brain functions (e.g. synaptic neurotransmission, 
neuroendocrine regulation, oxidative stress, adult neurogenesis 
etc.) (Chou et al., 2015; Seeman, 2002; Stojkovic et al., 2012), 
and even though we are certain that the sensitization and toler-
ance induced by these drugs must reflect the consequences of 
drug-induced neuroplastic changes, we do not fully understand 
the exact and critical mechanisms underlying the long-term 
sensitization and tolerance effects. There is not much research 
that has made an effort to connect drug-induced brain changes 
at the molecular/system level to the sensitization and tolerance 
at the behavioral level. This line of inquiry should be one of the 
focuses of future antipsychotic research. One related area of 
research is to investigate the neurobiological mechanism under-
lying the environmental control of the induction and expression 
of antipsychotic sensitization and tolerance. This work will help 
us gain better understanding of the neurobiological mechanisms 
underlying sensitization and tolerance effects.
Also, clinical evidence suggests that women react more favora-
bly to antipsychotic therapy than men (Szymanski et al., 1995), 
and preclinical evidence also suggests that sex of animals is an 
important factor in the modulation of antipsychotic response, with 
females tending to have increased sensitivity to antipsychotic treat-
ment due to lower D2 affinity compared to males (Pohjalainen 
et al., 1998). Our recent study also indicates that the magnitude of 
aripiprazole sensitization differs between male and female rats. 
With NIH’s increased emphasis on sex as a biological variable in 
the design and analysis of NIH-funded research involving animals, 
determining antipsychotic sensitization and its impact on basic 
behavioral and brain functions in both male and female animals 
becomes especially urgent. Unfortunately, all published antipsy-
chotic sensitization studies so far used only male animals. On the 
dosing regimens, much of this work only used a daily intermittent 
drug injection schedule for a short period of time (e.g. five days) 
and most only tested male normal rats, while both clinical and pre-
clinical evidence suggests that females tend to have delayed onset 
of psychopathology of schizophrenia (Han et al., 2012; Piontkewitz 
et al., 2012) and increased sensitivity to antipsychotic treatment 
due to lower D2 affinity compared to males (Pohjalainen et al., 
1998). It is thus important to examine sex differences in antipsy-
chotic sensitization and tolerance and use a variety of different 
dosing regiments, such as continuous treatment via osmatic min-
ipumps or drinking water or prolonged treatment for months.
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